帕米帕利联合替莫唑胺治疗小细胞肺癌致骨髓抑制1例
One case of myelosuppression caused by pamiparib in combination with temozolomide in the treatment of small cell lung cancer
杨宇晨 1赵宇婷 1李世琦 2宫佳宇 1苏日古嘎 2孙岩岩 3蔡智慧3
作者信息
- 1. 内蒙古医科大学研究生院(呼和浩特 010017)
- 2. 包头医学院研究生院(内蒙古包头 014060)
- 3. 内蒙古自治区人民医院肿瘤内科(呼和浩特 010017)
- 折叠
摘要
1例50岁男性广泛期小细胞肺癌患者使用帕米帕利联合替莫唑胺治疗,5 d后出现发热伴乏力,10 d后症状加重停药,入院诊断为化疗后骨髓抑制(4级).临床医师评估患者情况,采用Naranjo's评估量表进行不良反应关联性评价,判断骨髓抑制可能为帕米帕利和替莫唑胺共同诱导所致.经对症治疗后患者骨髓抑制缓解.本文探讨骨髓抑制与两药联合使用的相关性及处置措施,简述骨髓抑制发病的危险因素、治疗和预防,指导医务人员在使用类似方案过程中,根据不同个体及时调整治疗方案,加强药品不良反应监测与宣教,为临床安全用药提供参考.
Abstract
A 50-year-old male patient diagnosed with extensive stage small cell lung cancer was treated with pamiparib in combination with temozolomide.Five days later,the patient developed fever with fatigue.After 10 days,the patient stopped taking the drug due to worsening symptoms and was diagnosed with chemotherapy-induced myelosuppression(grade 4).The clinicist evaluated the patient's condition and assessed the association of adverse reactions using the Naranjo's evaluation scale,and concluded that myelosuppression may be induced by the combination of pamiparib and temozolomide.After symptomatic treatment,the patient's myelosuppression recovered completely.This article discusses the correlation between myelosuppression and the combination of the two drugs,provides treatment measures for this situation,briefly describes the risk factors of myelosuppression,treatment and prevention,and guides medical personnel to adjust the treatment plan in time according to different individuals in the process of using similar programs,and strengthens the monitoring and education of adverse drug reactions,so as to provide references for safe drug use.
关键词
小细胞肺癌/帕米帕利/替莫唑胺/骨髓抑制/药品不良反应Key words
Small cell lung cancer/Pamiparib/Temozolomide/Bone marrow suppression/Adverse drug reactions引用本文复制引用
出版年
2024
NETL
NSTL
万方数据